Aurinia Pharmaceuticals (NASDAQ: AUPH)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Aurinia Pharmaceuticals Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Aurinia Pharmaceuticals Company Info
Aurinia Pharmaceuticals Inc
News & Analysis
A patent settlement and improved financials sent the stock soaring.
Investors embraced the biotech's second-quarter results.
An analyst downgraded the stock.
Investors are none too pleased with the company's recent slew of hires.
Another buyout rumor is fueling the company's northward move today.
The biotech's underwhelming revenue guidance for 2022 is causing some shareholders to throw in the towel today.
These three stocks are poised for a major breakout in 2022.
The market is getting close to new highs again, but choppy performance is likely.
AUPH earnings call for the period ending September 30, 2021.
AUPH earnings call for the period ending June 30, 2021.
AUPH earnings call for the period ending December 31, 2020.
AUPH earnings call for the period ending March 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.